National Cancer Center Hospital, Tokyo, Japan.
Semin Hematol. 2010 Apr;47 Suppl 1:S5-7. doi: 10.1053/j.seminhematol.2010.01.015.
The most common subtype of T-/natural killer (NK) cell lymphoma in Japan is adult T-cell leukemia-lymphoma (ATL), which is associated with the human T-cell lymphotropic virus type I (HTLV-1). The investigators in Japan have conducted several clinical trials on multi-agent chemotherapy and stem cell transplantation for patients with ATL. They have also initiated several new clinical trials with a number of agents: an anti-CCR4 antibody, KW-0761; forodesine, a purine nucleoside phosphorylase inhibitor; and lenalidomide, an immunomodulatory agent. Clinical trials with pralatrexate, a folate analog, and denileukin diftitox, an immunoconjugate, are under discussion for patients with ATL and peripheral T-cell lymphoma (PTCL).
日本最常见的 T 细胞/自然杀伤 (NK) 细胞淋巴瘤亚型是成人 T 细胞白血病/淋巴瘤 (ATL)，它与人类 T 细胞嗜淋巴细胞病毒 I 型 (HTLV-1) 有关。日本的研究人员已经对 ATL 患者进行了多项关于多药物化疗和干细胞移植的临床试验。他们还启动了几项新的临床试验，涉及多种药物：抗 CCR4 抗体 KW-0761；嘌呤核苷磷酸化酶抑制剂氟达拉滨；免疫调节剂来那度胺。正在讨论用叶酸类似物普拉曲沙和免疫偶联物盐酸表柔比星治疗 ATL 和外周 T 细胞淋巴瘤 (PTCL) 患者的临床试验。
